A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients

Science Communicator Platform

Share By

A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients Publisher Pubmed

Soltani S^{1, 2} ; Zandi M^{1, 2} ; Shiri Aghbash P³ ; Rezaei M⁴ ; Mohammadzadeh N⁵ ; Afsharifar A⁶ ; Poortahmasebi V³

Source: Biotechnology and Applied Biochemistry Published:2022

Abstract

The necessity and impact of SARS-CoV2 on the world's health have led to developing and producing practical and useful vaccines for this deadly respiratory virus. Since April 2020, a vaccine for the virus has been developed. Given that comorbidities such as diabetes, hypertension, and cardiovascular disease are more prone to viruses and the risk of infection, vaccines should be designed to protect against high-risk respiratory illnesses. Including SARS, MERS, influenza, and the SARS-CoV-2 provide a safe immune response. Here, we review the information and studies that have been done to help develop strategies and perspectives for producing a safe and ideal vaccine to prevent COVID-19 in normal people, especially at high-risk groups such as diabetes patients. © 2020 International Union of Biochemistry and Molecular Biology, Inc.

Related Docs

View other Related Docs

1. Severe Acute Respiratory Syndrome-Coronavirus-2 Spike (S) Protein Based Vaccine Candidates: State of the Art and Future Prospects, Reviews in Medical Virology (2021)

2. Current Advances and Challenges in Covid-19 Vaccine Development: From Conventional Vaccines to Next-Generation Vaccine Platforms, Molecular Biology Reports (2022)

3. A Comprehensive Review of Mrna-Based Vaccines for Covid-19, a New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges, Current Topics in Medicinal Chemistry (2025)

Experts (# of related papers)

View all Related Experts

Nima Rezaei (4)

Mohammad Sharifzadeh (1)

Other Related Docs

4. Influenza Vaccine: Where Are We and Where Do We Go?, Reviews in Medical Virology (2019)

5. Recent Developments in Sars-Cov-2 Vaccines: A Systematic Review of the Current Studies, Reviews in Medical Virology (2023)

6. Delving Into Revolutionary Sars-Cov-2 Vaccine Approaches: Molecular and Virological Examinations; Principles of Sars-Cov-2 Vaccine Platform; [Adentrandose En Enfoques Revolucionarios De Vacunas Sars-Cov-2: Examenes Moleculares Y Virologicos; Principios De La Plataforma De Vacunas Sars-Cov-2], Vacunas (2024)

7. Overview of the Current Promising Approaches for the Development of an Effective Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-Cov-2) Vaccine, International Immunopharmacology (2020)

8. Sars-Cov-2: Current Trends in Emerging Variants, Pathogenesis, Immune Responses, Potential Therapeutic, and Vaccine Development Strategies, International Immunopharmacology (2021)

9. Vaccine Design and Delivery Approaches for Covid-19, International Immunopharmacology (2021)

10. The Chimera of S1 and N Proteins of Sars-Cov-2: Can It Be a Potential Vaccine Candidate for Covid-19?, Expert Review of Vaccines (2022)

11. Virtual Screening Based on the Structure of More Than 105 Compounds Against Four Key Proteins of Sars-Cov-2: Mpro, Srbd, Rdrp, and Plpro, Informatics in Medicine Unlocked (2022)

12. Vaccines for Covid-19: A Systematic Review of Feasibility and Effectiveness, Infectious Disorders - Drug Targets (2022)

13. A Review of Virus-Like Particle-Based Sars-Cov-2 Vaccines in Clinical Trial Phases, Iranian Journal of Pharmaceutical Research (2022)

14. Review on Approved and Inprogress Covid-19 Vaccines, Iranian Journal of Pharmaceutical Research (2022)

15. Design of a Multi-Epitope Vaccine Against Sars-Cov-2 Using Immunoinformatics Approach, International Journal of Biological Macromolecules (2020)

16. The Role of Mucosal Immunity and Recombinant Probiotics in Sars-Cov2 Vaccine Development, Probiotics and Antimicrobial Proteins (2021)

17. Covid-19: Transmission, Prevention, and Potential Therapeutic Opportunities, Clinica Chimica Acta (2020)

18. Recent Advances in Passive Immunotherapies for Covid-19: The Evidence-Based Approaches and Clinical Trials, International Immunopharmacology (2022)

19. An Overview of the Recent Findings of Cell-Based Therapies for the Treatment and Management of Covid-19, International Immunopharmacology (2021)

20. Recent Findings on the Coronavirus Disease 2019 (Covid-19); Immunopathogenesis and Immunotherapeutics, International Immunopharmacology (2020)

Style	Citing Format
MLA	Soltani S, et al.. "A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients." Biotechnology and Applied Biochemistry, vol. 69, no. 1, 2022, pp. 30-40.
APA	Soltani S, Zandi M, Shiri Aghbash P, Rezaei M, Mohammadzadeh N, Afsharifar A, Poortahmasebi V (2022). A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients. Biotechnology and Applied Biochemistry, 69(1), 30-40.
Chicago	Soltani S, Zandi M, Shiri Aghbash P, Rezaei M, Mohammadzadeh N, Afsharifar A, Poortahmasebi V. "A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients." Biotechnology and Applied Biochemistry 69, no. 1 (2022): 30-40.
Harvard	Soltani S et al. (2022) 'A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients', Biotechnology and Applied Biochemistry, 69(1), pp. 30-40.
Vancouver	Soltani S, Zandi M, Shiri Aghbash P, Rezaei M, Mohammadzadeh N, Afsharifar A, et al.. A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients. Biotechnology and Applied Biochemistry. 2022;69(1):30-40.
BibTex	@article{ author = {Soltani S and Zandi M and Shiri Aghbash P and Rezaei M and Mohammadzadeh N and Afsharifar A and Poortahmasebi V}, title = {A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients}, journal = {Biotechnology and Applied Biochemistry}, volume = {69}, number = {1}, pages = {30-40}, year = {2022} }
RIS	TY - JOUR AU - Soltani S AU - Zandi M AU - Shiri Aghbash P AU - Rezaei M AU - Mohammadzadeh N AU - Afsharifar A AU - Poortahmasebi V TI - A Review of Covid-19 Vaccines and Major Considerations for Diabetic Patients JO - Biotechnology and Applied Biochemistry VL - 69 IS - 1 SP - 30 EP - 40 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract